Loparine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loparine

Quick Facts

Property Description
Active Ingredient Enoxaparin Sodium
Form Sterile Aqueous Solution for Injection (often in pre-filled syringes)
Pharmacological Class Anticoagulant / Antithrombotic agent
Common Use Anticoagulation / Preventing blood clots (Thrombosis)
Origin Semisynthetic derivative of heparin (a glycosaminoglycan)

What Type of Medicine is Loparine?

Loparine is a prescription-only Antithrombotic agent and Anticoagulant with the active ingredient Enoxaparin Sodium. It is precisely classified as a Low Molecular Weight Heparin (LMWH).

This classification is clinically recognized for providing a more reliable and less variable anti-clotting response than traditional unfractionated heparin (UFH). The drug is supplied as a sterile aqueous solution for injection, often packaged in pre-filled syringes for subcutaneous administration. This form is particularly convenient for the prophylaxis of deep vein thrombosis (DVT) in patients with severely restricted mobility.

Enoxaparin Sodium: Composition, Origin, and Action

The active substance, Enoxaparin Sodium, is a semisynthetic derivative of heparin, chemically defined as a sulfated glycosaminoglycan. It is produced through a controlled chemical process from natural heparin, resulting in uniform molecular fragments. Its core action is characterized by a high ratio of activity against Factor Xa, a crucial enzyme in the clotting cascade, relative to Factor IIa (Thrombin). The high bioavailability of Enoxaparin Sodium when administered subcutaneously contributes significantly to its effectiveness in clinical practice, providing a reliable therapeutic effect.

What is the General Purpose of Anticoagulants like Loparine?

The general purpose of Loparine is to reduce the blood's capacity to form clots, thereby providing effective anticoagulation. By selectively modulating the clotting process through Factor Xa inhibition, the medicine helps to prevent the pathological development of thrombosis. This capability is fundamental for both thromboprophylaxis (preventive use) and achieving a state of controlled therapeutic anticoagulation, ensuring unobstructed blood flow through the vascular system.

Regulatory References

  1. FDA Label: ENOXAPARIN SODIUM
  2. NIH StatPearls

What side effects are possible with Loparine?

Possible side effects and safety information

The safety profile of Loparine (Enoxaparin Sodium), an anticoagulant, is officially documented by health authorities and is structured primarily around the risk of hemorrhage (bleeding), which is inherent to its mechanism of action. Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOC) as defined in regulatory texts.


Adverse Reactions and Frequency

Classification Examples of Documented Adverse Reactions
Very Common Hemorrhage, Increased hepatic enzymes (liver transaminases).
Common Thrombocytopenia (low platelets), Thrombocytosis, Injection site pain/hematoma, Cutaneous allergic reactions.
Rare Spinal/Epidural Hematoma, Severe Type II Heparin-Induced Thrombocytopenia (HIT), Anaphylaxis, Osteoporosis (associated with prolonged use).

Serious Adverse Reactions and Restrictions

Officially documented serious adverse reactions include Major Hemorrhage (such as intracranial bleeding) and Spinal or Epidural Hematoma, the latter being a rare but critical concern when the medicine is used with certain neuraxial procedures. Loparine is contraindicated in patients experiencing Active Major Bleeding or those with a history of Immune-Mediated Type II Heparin-Induced Thrombocytopenia.

Safety notes also address specific populations. Older adults may have an increased risk of bleeding. Patients with severe renal impairment require close monitoring due to altered drug clearance. Additionally, the risk of osteoporosis is officially noted with long-term exposure (several months).

Overdose and Emergency Response

Overdose Manifestations and Severity

Overdosage of Loparine is officially documented to result primarily in hemorrhage due to excessive anticoagulant activity. Clinical manifestations may include unusual bruising, blood in the urine, or black/bloody stools. Severe overdosage may lead to life-threatening major hemorrhagic complications, such as potentially fatal intracranial or retroperitoneal bleeding. The risk of serious outcomes, including spinal hematomas, is also noted in official regulatory information.

When to Seek Immediate Medical Help

Regulatory authorities mandate that individuals must seek immediate medical attention and contact the Poison Control Helpline if an overdose is suspected. Urgent medical services must be called if the individual has collapsed, is having a seizure, is experiencing trouble breathing, or is unable to be awakened, as written in official documentation.

Management and Specific Considerations

Management procedures may involve the administration of protamine sulfate, which is documented as the partially effective counteracting agent. Official labeling notes that protamine sulfate does not completely neutralize the drug's anti-factor Xa activity. Furthermore, certain populations, specifically patients with renal impairment or very low body weight, may experience increased drug exposure, elevating the risk for overdose symptoms and requiring careful clinical observation.

Therapeutic Uses of Loparine

What Loparine Treats: Main Uses and Benefits

Loparine (Enoxaparin Sodium) is considered relevant therapeutic support by addressing the risk and associated symptoms of pathological blood clotting, primarily across vascular and acute cardiac domains. Its main benefit is assisting with symptomatic relief by addressing the risk of symptoms that interfere with daily functioning.


The medication is commonly used to help manage symptoms related to heightened physiological activity across conditions characterized by periods of heightened symptoms. This includes the prevention of Deep Vein Thrombosis (DVT) after certain high-risk surgeries; the active management of established DVT and Pulmonary Embolism (PE); and supportive care in specific acute cardiac conditions like Acute Coronary Syndromes (ACS). Loparine is commonly used for patients who face severely restricted mobility during hospitalization or those in scenarios requiring temporary assistance in symptom stabilization. This use supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Facts: Therapeutic Focus

Property Description
Primary Focus Used for managing symptoms and addressing risks associated with pathological blood clotting (thrombosis).
Patient Benefit Contributes to improved comfort during periods of heightened symptoms and physiological stress.
Key Scenarios Prophylaxis following high-risk surgeries (e.g., hip/knee) and urgent support during acute cardiac events.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Loparine — Official Regulatory Information

This section outlines the official population eligibility and restriction rules for Loparine (Enoxaparin Sodium), as stated by government regulatory bodies.

Category Official Regulatory Status
Contraindicated Populations (Must Not Use) Active Major Bleeding; History of Heparin-Induced Thrombocytopenia (HIT); Known Hypersensitivity to Enoxaparin, Heparin, or Pork Products; Hypersensitivity to Benzyl Alcohol (in multi-dose vials).
Severe Organ Impairment Severe Renal Impairment (CrCl < 30 mL/min) requires use to be restricted and closely monitored. Use in End Stage Renal Disease (CrCl < 15 mL/min) is generally not recommended outside of haemodialysis. Caution is advised for hepatic impairment.
Age-Group Eligibility Pediatric Patients: Safety and efficacy have not been established. Geriatric Patients (75 years): Require monitoring for increased bleeding risk and are prohibited from receiving the initial IV bolus dose for specific acute conditions.
Pregnancy and Comorbidity Pregnancy: Use is supported only if clearly needed; preservative-free formulations are recommended. Use in patients with mechanical heart valves is not adequately studied and may pose a higher risk, especially in pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Loparine (Enoxaparin Sodium) has a documented interaction profile primarily focused on pharmacodynamic effects that heighten the risk of hemorrhage, a classification used in official regulatory documentation.

Interacting Substance Categories

Co-administration with other medicines that affect blood clotting or platelet function is officially documented as clinically significant. This includes product classes such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Salicylates, antiplatelet agents (e.g., Clopidogrel), thrombolytics, and other anticoagulants (including Warfarin sodium). Regulatory authorities typically require the discontinuation of hemorrhage-enhancing agents prior to initiating Loparine, or that close clinical monitoring be conducted.

Specific timing constraints are also mandated: co-administration with Warfarin during transition and with thrombolytics requires adherence to specific administration windows defined in official labeling.

Population and Clearance Considerations

A critical factor in the interaction profile is altered clearance: Severe Renal Impairment (creatinine clearance less than 30 mL/min) is officially documented as leading to increased drug exposure due to reduced elimination, requiring specialized management attention. Furthermore, Geriatric and low-weight patients are noted in official prescribing information as populations requiring monitoring for an increased risk of bleeding complications.

Finally, the multi-dose formulation contains the preservative Benzyl Alcohol, which is formally contraindicated for use in Infants and Neonates due to safety restrictions specified in the drug’s labeling.

Mechanism of Action

Targeted Potentiation of Antithrombin

Loparine initiates its action by binding to and significantly increasing the activity of the natural anticoagulant protein Antithrombin (ATIII). This molecular interaction enhances ATIII's inhibitory power, creating the complex required to accelerate the inactivation of key factors in the coagulation sequence.

Selective Inhibition of Coagulation Factor Xa

The activated Loparine-ATIII complex selectively targets and neutralizes Coagulation Factor Xa, an essential enzyme positioned at the convergence point of the clotting cascade. By selectively blocking Factor Xa, the mechanism prevents the generation of Thrombin, thereby diminishing the blood's capacity to form a stable fibrin clot.

Resulting Antithrombotic Effect

This molecular cascade reduces the systemic concentration of Thrombin, which is the enzyme responsible for converting fibrinogen into the structural fibrin mesh. The resulting physiological effect is a reduction in the capacity for blood coagulability, which promotes unobstructed blood flow within the vascular network.

Dosage and Administration Information

The use of Loparine (Enoxaparin Sodium) is governed by specific regulatory protocols defining administration route, dosing, frequency, and duration. This medicine is primarily administered by Subcutaneous (SC) injection into the abdominal wall; Intramuscular (IM) injection is forbidden. An Intravenous (IV) bolus is permitted only for the initial dose in specific Acute ST-Segment Elevation Myocardial Infarction (STEMI) regimens, requiring the IV line to be flushed with a compatible solution.

Official Administration Guidelines

Element Official Instruction
Route & Handling Primarily Subcutaneous (SC) Injection. IV bolus is only for initial dose in specific Acute STEMI. SC site must be rotated.
Dosing Schedule Prophylaxis: Fixed dose (e.g., 40 mg SC once daily). Treatment: Weight-based (e.g., 1 mg/kg SC every 12 hours).
Dose Adjustment Mandatory dose reduction for severe renal impairment (CrCl <30 mL/min), often switching to once daily dosing.
Course Duration Prophylaxis typically lasts 7 to 10 days. Therapeutic treatment requires a minimum of 5 days and is continued until concurrent oral therapy is stable.
Special Condition Treatment for DVT/PE requires co-administration with an oral anticoagulant (e.g., warfarin) until therapeutic targets are met.

The proper use of Loparine is structured by these detailed, context-dependent instructions, ensuring adherence to regulatory standards across different treatment scenarios.

Recent Clinical Evidence

Loparine: Recent Clinical Evidence

Phase III Clinical Trial Findings

Research has consistently evaluated whether clinical outcomes in specific patient populations were associated with treatment with Loparine. One key study’s findings indicated a change in symptom severity compared to placebo over a six-month period.

  • The primary outcome measure, based on the validated symptom scale, was explored in relation to treatment administration.
  • Adverse events were documented and evaluated across all study arms.

Further analysis explored the potential impact of the combination therapy in refractory cases.

Key Research Focus Areas

Studies have explored the role of this treatment in managing chronic conditions. Data from in vitro and animal models were used to investigate the drug’s relationship with cellular signaling pathways. This research helps inform the understanding of how the compound interacts with the body's systems.

  • A randomized, controlled study examined the relationship between dosage and therapeutic window.
  • A meta-analysis examined whether this treatment was associated with a change in pain perception.

Safety and Tolerability Profile

Studies, including those referencing comparator treatments, evaluated the tolerability of this drug during long-term use in the elderly.

  • Studies explored outcomes across various patient subgroups.

Overall, the body of evidence was considered in the context of therapeutic options. Further research continues to examine the long-term clinical significance of these observations.

Key Studies & References

  1. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis
  2. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism - NICE Guideline [NG89]

Frequently Asked Questions (FAQ)

Common questions about Loparine (FAQ)

Q: Can Loparine be taken with Tylenol or ibuprofen?

Official prescribing information advises caution or discontinuation of certain pain relievers, specifically nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, due to the heightened risk of bleeding. The label typically does not note a significant interaction with acetaminophen (Tylenol). The decision regarding any combined use of medications is typically made by a healthcare professional.


Q: What is the typical long-term experience for people taking Loparine?

The long-term safety profile of Loparine has been examined in various studies. Official regulatory documents indicate that when Low Molecular Weight Heparins are used for several months, there is a documented risk of developing osteoporosis (thinning of the bone). This specific long-term risk is an an important consideration noted in official product information.


Q: Are there any common side effects of Loparine that people often overlook?

The most frequently reported adverse reactions are hemorrhage (bleeding) and an increase in hepatic enzymes, which indicates a change in liver function. Other common effects include pain or bruising at the injection site and a change in the platelet count, called thrombocytopenia. These effects are typically described in official documents as the most common observations from clinical studies.


Q: Does Loparine have any known serious interactions with supplements like St. John's Wort?

Regulatory labeling warns against using Loparine concurrently with medicines or supplements that affect blood clotting or platelet function, as this increases the risk of hemorrhage. While St. John's Wort may not be named specifically, this general warning is a caution for any supplement with anti-clotting properties.


Q: Is Loparine safe to use during pregnancy or while breastfeeding?

Official prescribing information indicates that use of Loparine during pregnancy is supported only if the need is clear, and preservative-free formulations are typically recommended. Regarding breastfeeding, information suggests that Loparine is unlikely to pass into breast milk in clinically significant amounts due to its large molecular weight.


Q: How does Loparine interact with cold and flu medications?

Many common cold and flu medications contain ingredients that can affect the blood's ability to clot. Official warnings specifically advise caution with or discontinuation of products containing NSAIDs and Salicylates, which are common ingredients in cold and flu relief products known to increase the risk of bleeding when combined with Loparine.


Q: Is the onset of action different for different people taking Loparine?

Loparine is formulated as an injection to ensure high bioavailability, which generally contributes to a reliable therapeutic effect. However, official labeling notes that in patients with severe renal impairment (poor kidney function), the drug's clearance is significantly reduced. This reduced clearance means the medicine stays active longer in the body, which can increase the risk of bleeding.


Q: Can Loparine interact with herbal supplements used for sleep?

Official product warnings apply to any medication or supplement that affects blood clotting or platelet function, as this can increase the risk of hemorrhage. Caution is warranted for herbal supplements used for sleep if they are known to possess antiplatelet activity.


Q: How quickly should I expect Loparine to start working?

The time it takes for Loparine to reach its peak anti-clotting effect is defined in official pharmacokinetic studies. The maximum anti-Factor Xa activity is typically observed within three to five hours following a subcutaneous injection.


Q: Does Loparine affect sleep patterns or cause drowsiness?

Drowsiness or insomnia are not typically listed as common adverse reactions in the official regulatory documents for Loparine. However, some literature on Low Molecular Weight Heparins does note that neurological effects, such as headache or confusion, have been reported as rare side effects.


Q: What is the difference between Loparine and the generic version?

The active ingredient in Loparine is Enoxaparin Sodium. Regulatory bodies classify the generic version as therapeutically equivalent to the brand-name product, meaning it performs the same way in the body. However, the generic and brand-name formulations may differ in certain inactive ingredients or preservatives.


Q: Is it normal to feel a bit nauseous when first starting Loparine?

Official product labels list both nausea and diarrhea as potential side effects of Loparine. While these are not listed among the most commonly reported reactions, they are documented occurrences for some patients starting treatment.


Q: What should I do if I miss a scheduled time for Loparine?

Official administration guidance describes the action for a missed dose as skipping it and simply returning to the regular schedule for the next injection. Product information states that two doses should not be used at one time to make up for a dose that was missed.


Q: Do I need to get regular blood tests while on Loparine?

According to official regulatory documents, regular medical visits are important to monitor a patient's progress while on Loparine. Official information indicates that blood tests are needed to check for unwanted effects, most critically a decrease in the platelet count, which is medically referred to as thrombocytopenia.


Q: How long does Loparine stay in your system after you stop taking it?

Official pharmacokinetic data indicates that in individuals with normal kidney function, the anti-clotting activity (anti-Factor Xa half-life) of Loparine is approximately four to seven hours. However, this clearance time is noted to be slower in patients who have existing kidney impairment.


Q: What should be done if a child accidentally takes Loparine?

Official safety instructions state that the medication should be kept out of the sight and reach of children. Given the drug's effects, an accidental overdose may cause excessive bleeding, and this event typically necessitates immediate access to emergency medical services or calling a Poison Help line.


Q: Can Loparine cause changes in mood or personality?

Official labels do not list mood changes, depression, or personality changes as a common adverse reaction. However, some literature on Low Molecular Weight Heparins does note that side effects such as confusion have been reported as a potential effect.


Q: Does taking Loparine require any specific lifestyle changes?

Regulatory precautions advise patients to be aware of the increased risk of bleeding while using Loparine. This includes using extra care when shaving or brushing teeth, and awareness is advised regarding activities that may increase the overall risk of injury.


Q: What happens if I accidentally take two doses of Loparine close together?

Official instructions caution against taking two doses at once to cover a missed dose, as this constitutes an overdose. An overdose may cause excessive and serious bleeding, and this type of event typically necessitates immediate emergency medical attention.


Q: How often do patients need to see a doctor when starting Loparine?

Official monitoring guidelines advise that patients need to attend regular visits with their doctor to monitor their progress and check for any unwanted effects, particularly during the initial phase of treatment. The frequency of visits is determined by the prescribing healthcare professional.

How should Loparine be stored and disposed of?

Storage and Handling Requirements

Official labeling mandates that Loparine (Enoxaparin Sodium Injection) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be strictly protected from freezing and should not be refrigerated.

Pre-filled syringes are for single-use only. Before injection, the solution must be visually inspected to ensure it is clear and colorless to pale yellow, and free of particulate matter. The medication must be kept out of the sight and reach of children.

Disposal Instructions

Used syringes are classified as sharps and must be disposed of immediately in an approved sharps disposal container. Any unused or expired product must be discarded according to local pharmaceutical waste regulations. The medicine must not be disposed of via household wastewater or general trash unless permitted by local environmental rules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loparine found in:

A-Z Index: